Literature DB >> 30355093

Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.

Hee Tae Yu1, Pil-Sung Yang2, Tae-Hoon Kim1, Eunsun Jang1, Daehoon Kim1, Jae-Sun Uhm1, Jong-Youn Kim1, Hui-Nam Pak1, Moon-Hyoung Lee1, Gregory Y H Lip1,3, Boyoung Joung1.   

Abstract

Background and Purpose- Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial fibrillation. Concerns have been raised about an excess of stroke among patients with creatinine clearance (CrCl) >95 mg/mL treated with edoxaban. We assessed the real-world effectiveness and safety of edoxaban in atrial fibrillation patients in relation to CrCl. Methods- In the Korean National Health Insurance Service data during the period from January to December 2016, we identified 9537 edoxaban-treated patients. Effectiveness and safety outcomes were compared between high-dose edoxaban regimen (HDER, 60 mg daily, n=2840) and a propensity score-matched warfarin group (n=2840) and between low-dose edoxaban regimen (LDER, 30 mg daily, n=3016) and matched warfarin group (n=3016). Results- The median follow-up period was 5.0 months (interquartile range, 2-7 months). The mean age was 68 years, and 63% were men in HDER group, and the mean age was 73 years, and 52% were men in LDER group. Compared with warfarin, both HDER and LDER significantly decreased the risk for ischemic stroke or systemic embolism (S/SE; HDER: adjusted hazard ratio [aHR], 0.44; 95% CI, 0.31-0.64; LDER: aHR, 0.57; 95% CI, 0.42-0.78), major bleeding (HDER: aHR, 0.40; 95% CI, 0.26-0.61; LDER: aHR, 0.61; 95% CI, 0.43-0.85), and mortality (HDER: aHR, 0.34; 95% CI, 0.22-0.53; LDER: aHR, 0.55; 95% CI, 0.41-0.73). In patients with CrCl >95 mL/min, the incidence of S/SE was higher with LDER than warfarin and comparable between HDER and warfarin group. There was lower effectiveness for the prevention of S/SE with LDER compared with warfarin at higher CrCl levels ( P for interaction=0.023). Conclusions- In real-world practice, both doses of edoxaban were associated with reduced risks for S/SE, major bleeding, and mortality compared with warfarin. LDER had lower effectiveness for the prevention of S/SE compared with warfarin at higher levels of CrCl (>95 mL/min).

Entities:  

Keywords:  atrial fibrillation; edoxaban; heart failure; myocardial infarction; stroke; warfarin

Mesh:

Substances:

Year:  2018        PMID: 30355093     DOI: 10.1161/STROKEAHA.118.021387

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Tae-Min Rhee; So-Ryoung Lee; Eue-Keun Choi; Seil Oh; Gregory Y H Lip
Journal:  Front Cardiovasc Med       Date:  2022-06-10

2.  Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel.

Authors:  Nicola Mumoli; Claudia Amellone; Gianfranco Antonelli; Giuseppe Augello; Cosima Cloro; Alberto D'Alleva; Leonardo Di Ascenzo; Egidio Imbalzano; Renato Masala; Graziano Riccioni; Emanuele Romeo; Luca Rossi; Giosuè Santoro; Edoardo Sciatti; Antonio Tondo; Elisabetta Toso; Elio Venturini; Enrico Vizzardi; Giosuè Mascioli
Journal:  CJC Open       Date:  2020-07-23

Review 3.  Cardiovascular Research Using the Korean National Health Information Database.

Authors:  Eue Keun Choi
Journal:  Korean Circ J       Date:  2020-05-20       Impact factor: 3.243

4.  Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.

Authors:  Hee Tae Yu; Pil-Sung Yang; Eunsun Jang; Tae-Hoon Kim; Jae-Sun Uhm; Jong-Youn Kim; Hui-Nam Pak; Moon-Hyoung Lee; Gregory Y H Lip; Boyoung Joung
Journal:  J Am Heart Assoc       Date:  2020-06-04       Impact factor: 5.501

Review 5.  2018 Korean Guideline of Atrial Fibrillation Management.

Authors:  Boyoung Joung; Jung Myung Lee; Ki Hong Lee; Tae Hoon Kim; Eue Keun Choi; Woo Hyun Lim; Ki Woon Kang; Jaemin Shim; Hong Euy Lim; Junbeom Park; So Ryoung Lee; Young Soo Lee; Jin Bae Kim
Journal:  Korean Circ J       Date:  2018-12       Impact factor: 3.243

6.  Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.

Authors:  Thomas Raphael Meinel; Sebastién Frey; Marcel Arnold; Sarah Kendroud; Urs Fischer; Johannes Kaesmacher; Mirjam Rachel Heldner; Simon Jung
Journal:  PLoS One       Date:  2019-03-29       Impact factor: 3.240

7.  The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.

Authors:  Hyun Jin Oh; Kum Hei Ryu; Bum Joon Park; Byung-Ho Yoon
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

8.  The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.

Authors:  Oh Young Bang; Young Keun On; Myung-Yong Lee; Sung-Won Jang; Seongwook Han; Sola Han; Mi-Mi Won; Yoo-Jung Park; Ji-Min Lee; Hee-Youn Choi; Seongsik Kang; Hae Sun Suh; Young-Hoon Kim
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

9.  Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency.

Authors:  Wei-Chieh Lee; Min-Ping Huang
Journal:  Thromb J       Date:  2021-07-17

10.  Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.

Authors:  Gualtiero Palareti; Emilia Antonucci; Cristina Legnani; Daniela Mastroiacovo; Daniela Poli; Paolo Prandoni; Alberto Tosetto; Vittorio Pengo; Sophie Testa; Walter Ageno
Journal:  BMJ Open       Date:  2020-11-27       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.